Thiazolidinediones are associated with a decreased risk of atrial fibrillation compared with other antidiabetic treatment: A nationwide cohort study

European Heart Journal - Cardiovascular Pharmacotherapy

Volumn 3, Issue 3, 2017, Pages 140-146

  Pallisgaard, Jannik Langtved ^a,b   Lindhardt, Tommi Bo ^a,b   Staerk, Laila ^a,b   Olesen, Jonas Bjerring ^a   Torp Pedersen, Christian ^c   Hansen, Morten Lock ^d   Gislason, Gunnar Hilmar ^a,b,e,f  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c Institute for Health Science and Technology   (Denmark)

^d Zealand University Hospital   (Denmark)

^e The Danish National Foundation Research Center for Heart Arrhythmia   (Denmark)

^f UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

Atrial fibrillation; Complications; Diabetes mellitus; Glitazones; Prevention; Thiazolidinediones

Indexed keywords

BENZOIC ACID DERIVATIVE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1; INSULIN; METFORMIN; SULFONYLUREA; 2,4 THIAZOLIDINEDIONE DERIVATIVE;

ADULT; AGE; AGED; ARTICLE; ATRIAL FIBRILLATION; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DENMARK; DIABETES MELLITUS; FEMALE; HAZARD RATIO; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; REGISTER; RISK REDUCTION; SEX; ADOLESCENT; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; FOLLOW UP; HEALTH SURVEY; INCIDENCE; MIDDLE AGED; MULTICENTER STUDY; PREVALENCE; PROCEDURES; RETROSPECTIVE STUDY; RISK FACTOR; TIME FACTOR; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ATRIAL FIBRILLATION; DENMARK; DIABETES MELLITUS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; MIDDLE AGED; POPULATION SURVEILLANCE; PREVALENCE; REGISTRIES; RETROSPECTIVE STUDIES; RISK FACTORS; THIAZOLIDINEDIONES; TIME FACTORS; YOUNG ADULT;

EID: 85017091511     PISSN: 20556837     EISSN: 20556845     Source Type: Journal    
DOI: 10.1093/ehjcvp/pvw036     Document Type: Article

References (21)

1. Huxley RR, Filion KB, Konety S, Alonso A. Meta-analysis of cohort and casecontrol studies of type 2 diabetes mellitus and risk of atrial fibrillation. Am J Cardiol 2011;108:56-62.
2. Perez MV, Wang PJ, Larson JC, Soliman EZ, Limacher M, Rodriguez B, Klein L, Manson JE, Martin LW, Prineas R, Connelly S, Hlatky M, Wassertheil-Smoller S, Stefanick ML. Risk factors for atrial fibrillation and their population burden in postmenopausal women: The Women's Health initiative observational study. Heart 2013;99:1173-1178.
3. Pallisgaard JL, Lindhardt TB, Olesen JB, Hansen ML, Carlson N, Gislason GH. Management and prognosis of atrial fibrillation in the diabetic patient. Expert Rev Cardiovasc Ther 2015;13:643-651.
4. Pallisgaard JL, Schjerning A-M, Lindhardt TB, Procida K, Hansen ML, Torp-Pedersen C, Gislason GH. Risk of atrial fibrillation in diabetes mellitus: A nationwide cohort study. Eur J Prev Cardiol 2016;23:621-627.
5. Goudis CA, Korantzopoulos P, Ntalas IV, Kallergis EM, Liu T, Ketikoglou DG. Diabetes mellitus and atrial fibrillation: Pathophysiological mechanisms and potential upstream therapies. Int J Cardiol 2015;184:617-622.
6. Zhang Q, Liu T, Ng CY, Li G. Diabetes mellitus and atrial remodeling: Mechanisms and potential upstream therapies. Cardiovasc Ther 2014;32:233-241.
7. D'Ascia SL, D'Ascia C, Marino V, Lombardi A, Santulli R, Chiariello M, Santulli G. Cardiac resynchronisation therapy response predicts occurrence of atrial fibrillation in non-ischaemic dilated cardiomyopathy. Int J Clin Pract 2011;65:1149-1155.
8. Xie W, Santulli G, Reiken SR, Yuan Q, Osborne BW, Chen B-X, Marks AR. Mitochondrial oxidative stress promotes atrial fibrillation. Sci Rep 2015;5:11427.
9. Cariou B, Charbonnel B, Staels B. Thiazolidinediones and PPARc agonists: Time for a reassessment. Trends Endocrinol Metab 2012;23:205-215.
10. Straus DS, Glass CK. Anti-inflammatory actions of PPAR ligands: New insights on cellular and molecular mechanisms. Trends Immunol 2007;28:551-558.
11. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O'neill MC, Zinman B, Viberti G, ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427-2443.
12. Drugs@FDA: FDA Approved Drug Products [Internet]. https://www.accessdata. fda.gov/scripts/cder/drugsatfda/index.cfm (19 Oct 2015).
13. International Diabetes Federation Guideline Development Group. Global guideline for type 2 diabetes. Diabetes Res Clin Pract 2014;104:1-52.
14. Gu J, Liu X, Wang X, Shi H, Tan H, Zhou L, Gu J, Jiang W, Wang Y. Beneficial effect of pioglitazone on the outcome of catheter ablation in patients with paroxysmal atrial fibrillation and type 2 diabetes mellitus. Europace 2011;13:1256-1261.
15. Anglade MW, Kluger J, White CM, Aberle J, Coleman CI. Thiazolidinedione use and post-operative atrial fibrillation: A US nested case-control study. Curr Med Res Opin 2007;23:2849-2855.
16. Chao T-F, Leu H-B, Huang C-C, Chen J-W, Chan W-L, Lin S-J, Chen S-A. Thiazolidinediones can prevent new onset atrial fibrillation in patients with noninsulin dependent diabetes. Int J Cardiol 2012;156:199-202.
17. Liu T, Korantzopoulos P, Li G, Li J. The potential role of thiazolidinediones in atrial fibrillation. Int J Cardiol 2008;128:129-130.
18. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefèbvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Koranyi L, Laakso M, Mokan M, Norkus A, Pirags V, Podar T, Scheen A, Scherbaum W, Schernthaner G, Schmitz O, Skrha J, Smith U, Taton J, PROactive Investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): A randomised controlled trial. Lancet 2005;366:1279-1289.
19. Rix TA, Riahi S, Overvad K, Lundbye-Christensen S, Schmidt EB, Joensen AM. Validity of the diagnoses atrial fibrillation and atrial flutter in a Danish patient registry. Scand Cardiovasc J 2012;46:149-153.
20. Schramm TK, Gislason GH, Køber L, Rasmussen S, Rasmussen JN, Abildstrøm SZ, Hansen ML, Folke F, Buch P, Madsen M, Vaag A, Torp-Pedersen C. Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: A population study of 3.3 million people. Circulation 2008;117:1945-1954.
21. Kildemoes HW, Sørensen HT, Hallas J. The Danish National Prescription Registry. Scand J Public Health 2011;39:38-41.